



PATENT
Attorney Docket 044921-5029-01

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: **William E. Munger *et al.***

Application No. 09/960,706

Filed: **September 24, 2001**

Art Unit: 1631

Examiner: **Marjorie A. Moran**

For: **Identifying Drugs For and Diagnosis of Benign Prostatic Hyperplasia
Using Gene Expression Profiles**

INFORMATION DISCLOSURE STATEMENT UNDER 37 C.F.R. 1.97(d)

Pursuant to 37 C.F.R. 1.56 and 1.97(d), Applicants bring to the attention of the Examiner the documents listed on the attached PTO-1449. This Information Disclosure Statement is being filed, to the best of the undersigned's knowledge, after the mailing of a Final Office Action but before issuance of a Notice of Allowance. Under the provisions of 37 C.F.R. 1.97(d), a fee of \$180.00 as specified by 1.17(p) is required for the filing of this Information Disclosure Statement together with a statement as specified in 37 C.F.R. 1.97(e) which is supplied below. The Commissioner is hereby authorized to charge **\$180.00** to Deposit Account No. 50-0310 for payment of the Information Disclosure Statement fee as set forth on the accompanying transmittal form.

Copies of the listed documents are attached. Documents aa through ac were cited in an international search report dated December 10, 2004 which issued in a corresponding International Application, International Application PCT/US02/30182. A copy of the International Search Report is also attached. This Information Disclosure Statement is being filed within three months from the mailing date of the international search report.


Applicants respectfully request that the Examiner consider the listed documents and evidence that consideration by making appropriate notations on the attached form. This submission does not represent that a search has been made or that no better art exists and does not constitute an admission that the above-listed documents are material or constitute prior art. If the Examiner applies the documents as prior art against any claim in the application and Applicants determine that the cited document does not constitute prior art under United States law, Applicants reserve the right to present to the Office the relevant facts and law regarding the appropriate status of such document.

Applicants further reserve the right to take appropriate action to establish the patentability of the disclosed invention over the application and the references therein, should one or more of the documents be applied against the claims of the present application.


Except for issue fees payable under 37 C.F.R. 1.18, the Commissioner is hereby authorized by this paper to charge any additional fees during the entire pendency of this application including fees due under 37 C.F.R. 1.16 and 1.17 which may be required, including any required extension of time fees, or credit any overpayment to Deposit Account 50-0310. This paragraph is intended to be a **constructive petition for extension of time** in accordance with 37 C.F.R. 1.136(a)(3).

Dated: **March 7, 2005**
Morgan, Lewis & Bockius LLP
Customer No. **09629**
1111 Pennsylvania Avenue, N.W.
Washington, D.C. 20004
202-739-3000

Respectfully submitted
Morgan, Lewis & Bockius LLP



Robert Smyth
Registration No. 50,801



INFORMATION DISCLOSURE CITATION (Use several sheets if necessary) PTO Form 1449				Attorney Docket 044921-5029-01		Application No. 09/960,706			
				Applicants: William E. Munger <i>et al.</i>				Page 1 of 1	
				Filing Date: September 24, 2001		Group Art Unit: 1631			
U.S. PATENT DOCUMENTS									
Initial		Document No.	Date	Name	Class	Sub-Class	Filing Date		
	aa	2003/0134324 A1	07/17/2003	Munger <i>et al.</i>	435	7.1	06/05/2001		
FOREIGN PATENT DOCUMENTS									
		Document No.	Date	Country	Class	Sub-Class	Translation		
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, etc.)									
	ab	Elsasser-Beile <i>et al.</i> , Comparison of the Activation Status of Tumor Infiltrating and Peripheral Lymphocytes of Patients with Adenocarcinomas and Benign Hyperplasia of the Prostate, (2000) The Prostate, 45:1-7							
	ac	Shidaifat <i>et al.</i> , Gossypol Arrests Human Benign Prostatic Hyperplastic Cell Growth at G0/G1 Phase of the Cell Cycle, (1997) Anticancer Res. 17:1003-1010							
Examiner				Date Considered					
Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.									

Please type a plus sign (+) inside this box →



PTO/SB/08A (10-96)

Approved for use through 10/31/99. OMB 0651-0031
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet

1

of

1

Complete if Known

Application Number	09/960,706
Filing Date	9/24/2001
First Named Inventor	William MUNGER
Group Art Unit	1631
Examiner Name	Moran, M.
Attorney Docket Number	44921-5029-01-US

U.S. PATENT DOCUMENTS

Examiner Initials *	Cite No. ¹	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number	Kind Code ² (if known)			
		5,763,429		Bishop et al.	6/9/1998	
		5,882,864		An et al.	3/16/1999	

FOREIGN PATENT DOCUMENTS

Examiner Initials *	Cite No. ¹	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ₆
		Office ³	Number ⁴	Kind Code ⁵ (if known)				

OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS

Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		Bubendorf, L et al. Survey of gene amplifications during prostate cancer progression by high-throughput fluorescence in situ hybridization on tissue microarrays. (1999) Cancer Research 59:803-806.	
		Bubendorf, L et al. Hormone therapy failure in human prostate cancer: analysis by complementary DNA and tissue microarrays. (1999) J. Nat. Cancer Inst. 91(20):1758-1764.	


Examiner
Signature

Date
Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.



INFORMATION DISCLOSURE CITATION				Attorney Docket No. 44921-5029-01		Application No. 09/960,706	
(Use several sheets if necessary)				Applicants: William MUNGER <i>et al.</i> PAGE 1 of 1			
PTO Form 1449				Filing Date: September 24, 2001		Group Art Unit: Unassigned	
U.S. PATENT DOCUMENTS							
Examiner Initial		Document Number	Date	Name	Class	Sub Class	Filing Date
FOREIGN PATENT DOCUMENTS							
		Document Number	Date	Country	Class	Sub Class	<u>Translation</u> YES NO
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)							
		Brinkman, U. <i>et al.</i> PAGE-1 AN X CHROMOSOME-LINKED GAGE-LIKE GENE THAT IS EXPRESSED IN NORMAL AND NEOPLASTIC PROSTATE, TESTIS, AND UTERUS (1998) <i>Proc. Natl. Acad. Sci. (USA)</i> 96:20767-20762					
		Brinkman, U. <i>et al.</i> NOVEL GENES IN THE PAGE AND GAGE FAMILY OF TUMOR ANTIGENS FOUND BY HOMOLOGY WALKING IN THE dbEST DATABASE. (1999) <i>CANCER RES.</i> 59, 1445-148.					
		Isomura, M. <i>et al.</i> ISOLATION AND MAPPING OF RAB2L, A HUMAN CDNA THAT ENCODES A PROTEIN HOMOLOGOUS TO RALGDS. (1996) <i>Cyogenet.Cell Genet.</i> 74, 263-265.					
		Jacob, K. <i>et al.</i> OSTEONECTIN PROMOTES PROSTATE CANCER CELL MIGRATION AND INVASION: A POSSIBLE MECHANISM FOR METASTASIS TO BONE (1999) <i>Cancer Res.</i> 59:4453-4457					
		Nollet, F. <i>et al.</i> PHYLOGENETIC ANALYSIS OF THE CADHERIN SUPERFAMILY ALLOWS IDENTIFIDATION OF SIX MAJOR SUBFAMILIES BESIDES SEVERAL SOLITARY MEMBERS (2000) <i>J. Mol. Bio.</i> 299, 51-572					
		Seto, M.H. <i>et al.</i> PRO FOLD ANALYSIS OF THE B30.2-LIKE DOMAIN (1999) <i>PROTEINS</i> 35:235-49					
		Thomas, R. <i>et al.</i> DIFFERENTIAL EXPRESISON OF OSTONECTIN/SPARC DURING HUMAN PROSTATE CANCER PROGRESSION (2000) <i>Clin. Cancer Res.</i> 6:1140-1149					
Examiner				Date Considered			
Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.							